ClinicalTrials.gg
TerminatedNCT05122975Updated Sep 19, 2024

Treatment of an Inherited Ventricular Arrhythmia

A Phase 2 interventional study of S48168 (ARM210) and Matching Placebo in Catecholaminergic Polymorphic Ventricular Tachycardia Type 1, sponsored by Armgo Pharma, Inc.. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Armgo Pharma, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to challenges in recruiting patients.

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 154 studies in Tachycardia, Ventricular with a site in United States — 34 open to participants now, 40 under way, 2 of them phase 3. Tachycardia, Ventricular · United States.

Enrollment
89th of 107
8 · median 60
Started
2023
with 11 others
Phase 2
10 of 154
3 open now
Registered
119th of 154
by date

Among the 154 studies in Tachycardia, Ventricular with a site in United States, this one is the 89th largest by enrollment of the 107 interventional ones that give a count, is one of 12 that started in 2023, is one of 10 in phase 2, and was the 119th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

34 of the 154 studies in Tachycardia, Ventricular with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Tachycardia, Ventricular with a site in United States, or all of them as a file.
02

Study summary

The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease is associated with fatal changes in heart rhythms leading to sudden death with exercise or excessive excitement. It is due to mutations in the Ryanodine Receptor calcium release channel, which cause leaky channels leading to the disease. S48168 (ARM210) repairs these leaky channels and can be a disease-modifying therapy restoring normal function to the channels. This result would allow patients with CPVT to live normal, active lives. Funding Source- FDA OOPD.

03

Conditions studied

  • Catecholaminergic Polymorphic Ventricular Tachycardia Type 1

Keywords

  • Ventricular Arrhythmia
  • Calcium
  • Ryanodine Receptor 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following conditions to be eligible for enrollment into the study:

  1. Participant must be 18 to 65 years of age inclusive, at the time of signing the .
  2. Participants who are willing and able to comply with scheduled visits, study drug administration plan, study restrictions, and study procedures.
  3. Participants have a confirmed genetic diagnosis of CPVT1 and supporting clinical phenotype, including residual ventricular ectopy (a complexity score ≥ 2; requiring at minimum the presence of PVCs in bigeminy on exercise stress test) on a stable (at least 1 month) standard-of-care, CPVT1-directed treatment regimen as decided by their CPVT treating physician.
  4. Have a (BMI) ≤ 36 kg/m2 (inclusive) at screening.
  5. Male participants agree to not donate sperm from the first day of dosing of study drug until 5 half-lives plus 90 days (approximately 94 days) after the last dose of study drug.

    Female participants:

    eligible to participate if she is not pregnant or breastfeeding, and uses one of the following highly effective methods (from the first dose until 5 half-lives plus 90 days (approximately 94 days):

    • Prescribed hormonal oral contraceptives, vaginal ring, or transdermal patch.
    • Intrauterine device (IUD).
    • Intrauterine hormone-releasing system (IUS).
    • Depot/implantable hormone (e.g., Depo-Provera®, Implanon).
    • Bilateral tubal occlusion/ligation.
    • Sexual abstinence.
    • Refraining from heterosexual intercourse during the entire period of risk associated with the study requirements.
    • If the participant decides to become sexually active during the study, then one of the highly effective birth control methods must be used.

    OR

    Is a woman of non-; defined by at least 1 of the following criteria:

    • defined as 12 months of spontaneous amenorrhea without a medical cause and follicle stimulating hormone (FSH) serum level > 40 mIU/mL without the use of hormonal supplementation. Appropriated documentation of FSH levels is required.
    • Surgically sterile by hysterectomy and/or bilateral oophorectomy with appropriate documentation of surgical procedure.
    • Has a congenital condition resulting in no uterus.
  6. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  7. Daily use of medicines and dietary supplements need to be approved by the PI and Sponsor, or a drug/supplement-dependent prior to inclusion.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following conditions will exclude a participant from study enrollment:

  1. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose of study drug.
  2. History or presence of or idiosyncratic reaction to the study drug, related compounds, or inactive ingredients.
  3. or AST levels three times above the (ULN) at screening (isolated elevations of total \< 2 X ULN with direct bilirubin below the ULN will be included). A recheck for confirmation is allowed.
  4. History of documented, EEG-confirmed epileptic seizures.
  5. History of cancer (). Exceptions: (1) Subjects with adequately treated non-melanomatous carcinoma or carcinoma in situ of the cervix may participate in the trial; (2) Subjects with other malignancies who have been successfully treated > 10 years prior to the screening where in the judgment of the investigator has revealed no evidence of recurrence from the time of treatment through the time of the screening except those identified at the beginning of the exclusion criterion; or (3) Subjects who in the opinion of the investigator are highly unlikely to sustain a recurrence for the duration of the trial.
  6. Currently has uncontrolled diabetes defined as > 7% at screening visit or diabetic neuropathy.
  7. Estimated \< 40mL/minute at screening visit.
  8. abnormality on their screening and/or prior to first dosing resting , other than hypertensive related, or heart failure ( \< 30%) or other clinically significant structural heart disease.
  9. History of myocardial infarction in the last five years, or evidence of congestive heart failure.
  10. Ongoing medical condition that is deemed by the PI to interfere with the conduct or assessments of the study or safety of the subject.
  11. Unable to refrain from or anticipates the use of:

    • Any non-approved medicines (prescribed standard-of-care for CPVT is approved) and/or dietary supplements beginning 14 days prior to the first dose of study drug and throughout the study. Thyroid hormone replacement medication may be permitted if subject has been on same stable dose for the last 3 months prior to the first dose of study drug.
    • Any drugs known to be significant inducers or inhibitors of CYP2C8 enzymes for 28 days prior to the first dose of study drug and throughout the study. Is currently taking any drug which raises gastric pH, including proton pump inhibitors or H2 antagonists. Antacids may be used if taken at night.
  12. Participation in clinical trials for other therapeutic drugs simultaneously or within the 4 weeks prior to the first dose of study drug.
  13. Plasma donation within 7 days prior to the first dose of study drug.
  14. Donation of blood or significant blood loss within 56 days prior to the first dose of study drug.
  15. Is mentally or legally incapacitated at the time of screening visit.
  16. Is unable to take orally administered tablets.
  17. Is an immediate family member of the Sponsor or employee of the clinical site or may consent under duress.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    S48168 (ARM210) once daily for 28 days

    Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.

    Drug: S48168 (ARM210)

  • Placebo comparator
    Matching Placebo once daily for 28 days

    Oral dose of placebo once daily on top of standard of care regimen for 28 days.

    Drug: Matching Placebo

Interventions

  • Ryanodine Receptor modulator

  • DrugMatching Placebo

    Placebo of same size and consistency as S48168 (ARM210)

06

What researchers measure

Primary outcomes

  1. The effect of S48168 (ARM210) treatment on the amount and complexity of exercise-• Change in ectopy score from baseline to Day 28 versus placebo (pre-dose Period 1 baseline to Day 28 Period 1 versus Day 28 Period 2

    Analysis of ECG recordings during exercise testing examining for abnormal beats occurring with exercise, such as premature ventricular contractions (PVCs). The scale is as follows: Ectopy Scoring Scale (0-4) No ectopy 0 Isolated PVCs 1 Bigeminy 2 Couplets 3 Non-sustained VT 4 van der Werf, C., et al. (2011). "Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia." J Am Coll Cardiol 57(22): 2244-2254.

    Time frame: 28 days

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    The number and severity of adverse events that can be related to treatment with S48168 (ARM210)

    Time frame: 28 days

Other outcomes

  1. The pharmacokinetics (PK) of a 28-day administration of S48168 (ARM210) in patients

    Day one and day 28 maximal plasma concentration (Cmax)

    Time frame: 28 days

  2. Total Plasma Drug Exposure of a 28-day administration of S48168 (ARM210) in patients

    Measurement of the area under the curve (AUC) at day 1 and day 28 in plasma

    Time frame: 28 days

  3. Evaluation of a novel expanded ectopy scale in exercise stress tests which qualifies both the ectopy and the heart rate at which it occurs.

    Expanded novel ectopy scale No ectopy 0 points PVCs only 1 point Bigeminy 2 points Couplets 5 points Non-sustained VT 10 points Add 5 points for ectopy onset at heart rate \<=120 bpm; 3 points for ectopy onset at heart rate \> 120 but \<= 150 bpm; 1 point for ectopy onset at heart rate \> 150 bpm

    Time frame: 28 days

  4. Evaluation of heart rhythm throughout treatment periods

    Using a wearable cardiac monitoring device continuously throughout the treatment periods to determine frequency of abnormal beats including PVCs, bigeminy and couplets in the active and placebo treatment periods

    Time frame: 28 days

07

Study locations

2 sites
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Amsterdam University Medical Center
    Amsterdam-Zuidoost, 91105, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Apr 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Nov 17, 2021
StartActual
Aug 1, 2023
Primary completionActual
Apr 1, 2024
CompletionActual
Apr 1, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05122975
Lead sponsor
Armgo Pharma, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2021
Start date
Aug 1, 2023
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024
Last update
Sep 19, 2024

Study contacts

Michael J Ackerman, MD PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surlorian

Start the discussion